Xiaokui Mo

9.5k citations

217 papers · 6.1k indexed · 1 hit paper · h-index 41

Impact in

Cancer Research top 1%
- MicroRNA in disease regulation
- Cancer, Lipids, and Metabolism
- Cancer, Hypoxia, and Metabolism
Biological Psychiatry top 5%

Papers in

Genetics 40
- Chronic Lymphocytic Leukemia Research 35
Immunology 55
- Immune Cell Function and Interaction 22
- Immunodeficiency and Autoimmune Disorders 10

Co-authors: Natarajan Muthusamy John C. Byrd Kathi J. Kemper Rami Khayat Phillip G. Popovich Arunark Kolipaka Arnab Chakravarti Jodie C.E. Hall
Journals: Blood (18 papers)The Journal of Immunology (10 papers)Clinical Cancer Research (9 papers)PLoS ONE (8 papers)Journal of Biological Chemistry (7 papers)
Partner nations: United States China Taiwan

In The Last Decade

Xiaokui Mo

207 papers receiving 6.0k citations

Hit Papers

align trajectories log scale

Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells 2017 · 447 citations

Peers

Countries citing papers authored by Xiaokui Mo

Since Specialization

Citations

This map shows the geographic impact of Xiaokui Mo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaokui Mo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaokui Mo more than expected).

Fields of papers citing papers by Xiaokui Mo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaokui Mo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaokui Mo. The network helps show where Xiaokui Mo may publish in the future.

Co-authors

The 25 scholars most cited alongside Xiaokui Mo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Xiaokui Mo Line = papers co-authored together Xiaokui Mo links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Targeting PGM3 abolishes SREBP-1 activation-hexosamine synthesis feedback regulation to effectively suppress brain tumor growth Science Advances ·Huali Su, Yubin Zhong, Liqing He, Feng Geng, Xinmin Yin, Yongjun Kou, Chengyao Chiang, Xiaokui Mo, Yunzhou Fan, Yanwei Liu, Qiang Wang, Shino Magaki, Timothy F. Cloughesy, Étienne Lefai, William H. Yong, Arnab Chakravarti, Xiang Zhang, Deliang Guo	2025	1
2	Exogenous Sequences in Tumors and Immune Cells (Exotic): A Tool for Estimating the Microbe Abundances in Tumor RNA-seq Data Cancer Research Communications ·Rebecca Hoyd, Caroline E. Wheeler, YunZhou Liu, Malvenderjit S. Jagjit Singh, Mitchell Muniak, Ning Jin, Nicholas Denko, David P. Carbone, Xiaokui Mo, Daniel Spakowicz	2023	4
3	Dose-Specific Intratumoral GM-CSF Modulates Breast Tumor Oxygenation and Antitumor Immunity The Journal of Immunology ·Nicole E. Mihalik, Kayla J. Steinberger, Alyson M. Stevens, Andrey A. Bobko, E. Hannah Hoblitzell, Oxana Tseytlin, Halima Akhter, Sebastian A. Dziadowicz, Lei Wang, Ryan C. O’Connell, Kelly L. Monaghan, Gangqing Hu, Xiaokui Mo, Valery V. Khramtsov, Mark Tseytlin, Benoît Driesschaert, Chi‐Keung Wan, Timothy D. Eubank	2023	7
4	Dopamine Prevents Ultraviolet B–induced Development and Progression of Premalignant Cutaneous Lesions through its D2 Receptors Cancer Prevention Research ·Kai Lu, Madhavi Bhat, Sara Peters, Rita Mitra, Xiaokui Mo, Tatiana M. Oberyszyn, Partha Dasgupta, Sujit Basu	2021	2
5	Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia Clinical Cancer Research ·Shanmugapriya Thangavadivel, Qiuhong Zhao, Narendranath Epperla, Lindsey Rike, Xiaokui Mo, Mohamed Badawi, Darlene M. Bystry, Mitch A. Phelps, Leslie A. Andritsos, Kerry A. Rogers, Jeffrey J. Jones, Jennifer A. Woyach, John C. Byrd, Farrukh T. Awan	2020	3
6	Tumor Volume Dynamics on kV-CBCT During Definitive Radiation Therapy for Locally Advanced NSCLC: Implications for Prognosis and Adaptive Radiation Therapy International Journal of Radiation OncologyBiologyPhysics ·Patrick Wald, Xiaokui Mo, C. Barney, J.C. Grecula, Terence M. Williams, Kaisa Haglund, Jose G. Bazan, M.X. Welliver	2017	1
7	Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells Cancer Immunology Research ·Rebekah L. Browning, William H. Byrd, Nikhil Gupta, Jeffrey A. Jones, Xiaokui Mo, Erin Hertlein, Lianbo Yu, Natarajan Muthusamy, John C. Byrd	2016	13
8	Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1–Mediated Lipogenesis Clinical Cancer Research ·Feng Geng, Xiang Cheng, Xiaoning Wu, Ji Young Yoo, Chunming Cheng, Jeffrey Yunhua Guo, Xiaokui Mo, Peng Ru, Brian Hurwitz, Sunghak Kim, José Javier Otero, Vinay K. Puduvalli, Étienne Lefai, Jianjie Ma, Ichiro Nakano, Craig Horbinski, Balveen Kaur, Arnab Chakravarti, Deliang Guo	2016	244
9	A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer Molecular Cancer Therapeutics ·Erin M. Bertino, Elizabeth L. McMichael, Xiaokui Mo, Prashant Trikha, Melanie E. Davis, Bonnie Paul, Michael R. Grever, William E. Carson, Gregory A. Otterson	2016	22
10	Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma Molecular Cancer Therapeutics ·Andrew Stiff, Enrico Caserta, Douglas W. Sborov, Gerard J. Nuovo, Xiaokui Mo, Sarah Schlotter, Alessandro Canella, Emily Smith, Joseph Badway, Matthew Old, Alena Cristina Jaime‐Ramirez, Pearlly S. Yan, Don M. Benson, John C. Byrd, Robert A. Baiocchi, Balveen Kaur, Craig C. Hofmeister, Flavia Pichiorri	2016	31
11	The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma Molecular Cancer Therapeutics ·Hemant K. Bid, Doris A. Phelps, Linlin Xaio, Denis C. Guttridge, Jiayuh Lin, Cheryl A. London, Laurence H. Baker, Xiaokui Mo, Peter J. Houghton	2016	66
12	IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells Clinical Cancer Research ·Elizabeth L. McMichael, Alena Cristina Jaime‐Ramirez, Kristan Guenterberg, Eric Luedke, Lakhvir S. Atwal, Amanda R. Campbell, Zhiwei Hu, Armika S. Tatum, Sri Vidya Kondadasula, Xiaokui Mo, Susheela Tridandapani, Mark Bloomston, E. Christopher Ellison, Terence M. Williams, Tanios Bekaii‐Saab, William E. Carson	2016	55
13	Are Mindfulness and Self-Compassion Associated with Sleep and Resilience in Health Professionals? The Journal of Alternative and Complementary Medicine ·Kathi J. Kemper, Xiaokui Mo, Rami Khayat	2015	182
14	SMARCA4 /BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non–Small Cell Lung Cancer Clinical Cancer Research ·Erica H. Bell, Arup R. Chakraborty, Xiaokui Mo, Ziyan Liu, Konstantin Shilo, Simon Kirste, Petra Stegmaier, Maureen McNulty, Niki Karachaliou, Rafael Rosell, Gerold Bepler, David P. Carbone, Arnab Chakravarti	2015	115
15	AMPK Reverses the Mesenchymal Phenotype of Cancer Cells by Targeting the Akt–MDM2–Foxo3a Signaling Axis Cancer Research ·Chih-Chien Chou, Kuen‐Haur Lee, I‐Lu Lai, Dasheng Wang, Xiaokui Mo, Samuel K. Kulp, Charles L. Shapiro, Ching‐Shih Chen	2014	147
16	Dual Targeting of the Type 1 Insulin-like Growth Factor Receptor and Its Ligands as an Effective Antiangiogenic Strategy Clinical Cancer Research ·Hemant K. Bid, Cheryl A. London, Jin Gao, Haihong Zhong, Robert E. Hollingsworth, Soledad Fernández, Xiaokui Mo, Peter J. Houghton	2013	18
17	Cytomegalovirus Contributes to Glioblastoma in the Context of Tumor Suppressor Mutations Cancer Research ·Richard L. Price, Jieun Song, Katherine Bingmer, Tae Hyong Kim, Ji-Yeun Yi, Michal O. Nowicki, Xiaokui Mo, Todd Hollon, Eric Murnan, Christopher Alvarez‐Breckenridge, Soledad Fernández, Balveen Kaur, Andreana L. Rivera, Michael Oglesbee, Charles H. Cook, E. Antonio Chiocca, Chang‐Hyuk Kwon	2013	50
18	DNA Demethylating Agents Synergize with Oncolytic HSV1 against Malignant Gliomas Clinical Cancer Research ·Kazuo Okemoto, Kazue Kasai, Benjamin Wagner, Amy Haseley, Hans Meisen, Chelsea Bolyard, Xiaokui Mo, Allison Wehr, Amy Lehman, Soledad Fernández, Balveen Kaur, E. Antonio Chiocca	2013	23
19	Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma Clinical Cancer Research ·Hemant K. Bid, Aaron Kibler, Doris A. Phelps, Sagymbek Manap, Linlin Xiao, Jiayuh Lin, David Capper, Duane Oswald, Brian Geier, Mariko DeWire, Paul D. Smith, Raushan T. Kurmasheva, Xiaokui Mo, Soledad Fernández, Peter J. Houghton	2013	49
20	Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies Clinical Cancer Research ·Yicheng Mao, Georgia Triantafillou, Erin Hertlein, William H. Towns, Matthew Stefanovski, Xiaokui Mo, David Jarjoura, Mitch A. Phelps, Guido Marcucci, Ly James Lee, David M. Goldenberg, Robert J. Lee, John C. Byrd, Natarajan Muthusamy	2012	26

About Xiaokui Mo

Xiaokui Mo is a scholar working on Genetics, Immunology, Cancer Research, Radiology, Nuclear Medicine and Imaging and Oncology, having authored 217 papers that have together received 6.1k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (35 papers), Immune Cell Function and Interaction (22 papers), Monoclonal and Polyclonal Antibodies Research (16 papers), MicroRNA in disease regulation (14 papers), Lymphoma Diagnosis and Treatment (13 papers), CAR-T cell therapy research (12 papers), Ultrasound Imaging and Elastography (11 papers) and Immunodeficiency and Autoimmune Disorders (10 papers). The work is most often cited by research in Cancer Research (1.2k citations), Biological Psychiatry (144 citations), Genetics (603 citations), Immunology (1.1k citations) and Oncology (1.1k citations). Xiaokui Mo has collaborated with scholars based in United States, China and Taiwan. Frequent co-authors include Natarajan Muthusamy, John C. Byrd, Kathi J. Kemper, Rami Khayat, Phillip G. Popovich, Arunark Kolipaka, Arnab Chakravarti, Jodie C.E. Hall, Thomas D. Schmittgen and Jinmai Jiang. Their work appears in journals such as Blood, The Journal of Immunology, Clinical Cancer Research, PLoS ONE and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact